Back to Search
Start Over
Inflammatory markers S100A8/A9 and metabolic alteration for evaluating signs of early phase toxicity of anticancer agent treatment.
- Source :
-
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2022 Nov; Vol. 169, pp. 113421. Date of Electronic Publication: 2022 Sep 10. - Publication Year :
- 2022
-
Abstract
- Anticancer agents can cause various side effects, including tissue damages/inflammatory reactions. Drug-responsive biomarkers are essential for evaluating drug toxicity in disease processes. S100 calcium-binding proteins A8/A9 (S100A8/A9) are highly expressed in neutrophils and monocytes/macrophages accumulated at inflammatory sites and are known to be related to tissue damage/inflammation; however, their response to drug toxicity has not been reported. Herein, we investigated the effects of anticancer agents (doxorubicin, cisplatin, and docetaxel) on S100A8/A9 gene expression profiles in four representative tissues (heart, kidney, liver, and lung) in normal C57BL/6J mice. Both S100A8/A9 expression was transiently or time-dependently elevated in four tissues within 48 h after dosing of the three anticancer agents under toxicity-inducing conditions. S100A8/A9 patterns differed among agents and tissues. This result suggests that S100A8/A9 is useful for evaluating anticancer agent-induced tissue damage. Metabolomic analysis revealed that some metabolites showed temporal patterns similar to that of S100A8/A9 expression. The amounts of fumarate (doxorubicin-treated heart), tyrosine (cisplatin-treated kidney), acetylcarnosine (doxorubicin-treated liver), and 2-phosphoglycerate (docetaxel-treated lung) showed similar patterns to that of S100A8/A9 expression. Although these metabolites showed different behaviors between tissues and serum, they may be useful marker candidates for evaluating anticancer agent-induced tissue damage at an earlier stage after dosing.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Mice
Cisplatin administration & dosage
Cisplatin toxicity
Docetaxel administration & dosage
Docetaxel toxicity
Doxorubicin administration & dosage
Doxorubicin toxicity
Fumarates analysis
Mice, Inbred C57BL
Tyrosine analysis
Antineoplastic Agents administration & dosage
Antineoplastic Agents toxicity
Biomarkers, Pharmacological metabolism
Calgranulin A genetics
Calgranulin A metabolism
Calgranulin B genetics
Calgranulin B metabolism
Inflammation chemically induced
Inflammation metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-6351
- Volume :
- 169
- Database :
- MEDLINE
- Journal :
- Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
- Publication Type :
- Academic Journal
- Accession number :
- 36100043
- Full Text :
- https://doi.org/10.1016/j.fct.2022.113421